References
1a
Zimmermann J.
Buchdunger E.
Mett H.
Meyer T.
Lydon NB.
Traxler P.
Bioorg. Med. Chem. Lett.
1996,
6:
1221
1b
Paul R.
Hallett WA.
Hanifin JW.
Riech MF.
Johnson BD.
Lenhard RH.
Dusza JP.
Kerwar SS.
Lin Y.
Pickett WC.
Seifert CM.
Torley LW.
Tarrant ME.
Wrenn S.
J. Med. Chem.
1993,
36:
2716
1c
Bennett GB.
Mason RB.
Alden LJ.
Roach JB.
J. Med. Chem.
1978,
21:
623
1d
Moffat D.
Davis P.
Hutchings M.
Davis J.
Berg D.
Batchelor M.
Johnson J.
O’Connell J.
Martin R.
Crabbe T.
Delgado J.
Perry M.
Bioorg. Med. Chem. Lett.
1998,
9:
3351
1e
Bingham AH.
Davenport RJ.
Gowers L.
Knight RL.
Lowe C.
Owen DA.
Parry DM.
Pitt WR.
Bioorg. Med. Chem. Lett.
2004,
14:
409
2
Brown DJ.
Evans RF.
Cowden WB.
Fenn MD.
The Pyrimidines, In The Chemistry of Heterocyclic Compounds
Vol. 52:
John Wiley & Sons;
New York:
1994.
3a
Dawood KM.
Kandeel ZE.
Farag AM.
Heteroat. Chem.
1999,
10:
417
3b
Sansebastiano L.
Mosti L.
Menozzi G.
Schenone P.
Muratore O.
Petta A.
Debbia E.
Schito AP.
Scito GC.
Il Farmaco
1993,
48:
335
3c
Porcheddu A.
Giacomelli G.
De Luca L.
Ruda AM.
J. Comb. Chem.
2004,
6:
105
3d Davis PD, Hutchings MC, and Moffat DFC. inventors; PCT Int. Appl. WO 9841512 A1.
; Chem. Abstr. 1998, 129, 275921
3e Davis PD, Moffat DFC, Davis JM, and Hutchings MC. inventors; PCT Int. Appl. WO 9719065 A1.
; Chem. Abstr. 1997, 127, 81461
4a
Abdula RF.
Fuhr KH.
J. Org. Chem.
1978,
43:
4248
4b
SanMartín R.
de Marigorta EM.
Domínguez E.
Tetrahedron
1994,
50:
2255
4c
Pleier AK.
Glas H.
Grosche M.
Sirch P.
Thiel WR.
Synthesis
2001,
55
5a
Hughes JL.
Liu RC.
Enkoji T.
Smith CM.
Bastian JW.
Luna PD.
J. Med. Chem.
1975,
18:
1077
5b
Pazdera P.
Potacek M.
Chem. Pap. - Chem. Zvesti
1988,
42:
527
6 Guanidine 3a and enaminone 2a were dissolved in MeOH and K2CO3 was added. The solvent was removed in vacuo and the solid was heated at 145 °C for 2 h (solvent-free reaction conditions).
7a
Berrueta LA.
Gallo B.
Vicente F.
Chromatographia
1995,
40:
474
7b
Nilsson KJ.
J. Chromatogr., A
2000,
885:
305
8
General Procedure for the Preparation of 4-Substituted N
-Phenyl-2-aminopyrimidines.
Guanidines 3a-f (0.12 mmol) and enaminones 2a-h (0.1 mmol) were placed in 2 mL vials and DBU was added (60 µL, 0.4 mmol). The mixture was heated and vigorously stirred for 1 h at 120 °C. After cooling to r.t., CH2Cl2 (2 mL) was added and solution was loaded onto silica SPE column (1 g). The desired product was collected by eluting the silica column with n-hexane-EtOAc (1:1, 2 × 5 mL). After removal of the solvent, the final product was obtained as a yellow solid. All new compounds were fully characterized.
Selected Analytical Data.
Compound 1a: MS (ESI): m/z = 356.2 [M + H+]. 1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 3 H), 3.89 (s, 6 H), 7.03 (s, 2 H), 7.11 (d, J = 5.3 Hz, 1 H), 7.17 (t, J = 7.0 Hz, 2 H), 7.59 (s, 1 H), 8.11-8.07 (m, 2 H), 8.45 (d, J = 5.3 Hz, 1 H).
Compound 1n: MS (ESI): m/z = 336.2 [M + H+]. 1H NMR (300 MHz, CDCl3): δ = 1.73-1.83 (m, 6 H), 1.99 (m, 6 H), 2.11 (m, 3 H), 3.85 (s, 3 H), 6.58 (ddd, J = 8.2 Hz, J = 2.4 Hz, J = 0.8 Hz, 1 H), 6.69 (d, J = 5.3 Hz, 1 H), 7.04 (ddd, J = 8.1 Hz, J = 2.0 Hz, J = 0.8 Hz, 1 H), 7.21 (dd, J = 8.2 Hz, J = 8.1 Hz, 1 H), 7.46 (br s, 1 H), 7.65 (dd, J = 2.4 Hz, J = 2.2 Hz, 1 H), 8.32 (d, J = 5.1 Hz, 1 H).